One-year outcomes of acute decompensated systolic heart failure in Taiwan: Lessons from TSOC-HFreF registry

Hung Yu Chang, Chun Chieh Wang, Yen Wen Wu, Pao Hsien Chu, Chih Cheng Wu, Chih Hsin Hsu, Ming Shien Wen, Wen Chol Voon, Wei Shiang Lin, Jin Long Huang, Shyh Ming Chen, Ning I. Yang, Heng Chia Chang, Kuan Cheng Chang, Shih Hsien Sung, Kou Gi Shyu, Jiunn Lee Lin, Guang Yuan Mar, Kuei Chuan Chan, Jen Yuan KuoJi Hung Wang, Zhih Cherng Chen, Wei Kung Tseng, Wen Jin Cherng, Wei Hsian Yin*

*Corresponding author for this work

Research output: Contribution to journalJournal Article peer-review

35 Scopus citations


Background: Heart failure (HF) is a global health problem. The Taiwan Society of Cardiology-Heart Failure with reduced Ejection Fraction (TSOC-HFrEF) registry was a multicenter, observational survey of patients admitted with HFrEF in Taiwan. The aim of this study was to report the one-year outcome in this large-cohort of hospitalized patients presenting with acute decompensated HFrEF. Methods: Patients hospitalized for acute HFrEF were recruited in 21 hospitals in Taiwan. A total of 1509 patients were enrolled into the registry by the end of October 2014. Clinical status, readmission rates and dispensed medications were collected and analyzed 1 year after patient index hospitalization. Results: Our study indicated that re-hospitalization rates after HFrEF were 31.9% and 38.5% at 6 and 12 months after index hospitalization, respectively. Of these patients, 9.7% of themwere readmittedmore than once. At 6 and 12 months after hospital discharge, all-cause mortality rates were 9.5% and 15.9%, respectively, and cardiovascular mortality rateswere 6.8% and 10.5%, respectively. Twenty-three patients (1.5%) underwent heart transplantation. During a follow-up period of 1 year, 46.4% of patients were free from mortality, HF re-hospitalization, left ventricular assist device use and heart transplantation. At the conclusion of follow-up, 57.5% of patients were prescribed either with angiotensin-converting enzyme inhibitors or angiotensin receptor blockers; also, 66.3% were prescribed with beta-blockers and 40.8% were prescribed with mineralocorticoid receptor antagonists. Conclusions: The TSOC-HFrEF registry showed evidence of suboptimal practice of guideline-directed medical therapy and high HF re-hospitalization rate in Taiwan. The one-year mortality rate of the TSOC-HFrEF registry remained high. Ultimately, our data indicated a need for further improvement in HF care.

Original languageEnglish
Pages (from-to)127-138
Number of pages12
JournalActa Cardiologica Sinica
Issue number2
StatePublished - 03 2017
Externally publishedYes

Bibliographical note

Publisher Copyright:
© 2017, Republic of China Society of Cardiology. All rights reserved.


  • Beta-blocker
  • Heart failure
  • Mortality
  • Renin-angiotensin blockade
  • Taiwan
  • Treatment


Dive into the research topics of 'One-year outcomes of acute decompensated systolic heart failure in Taiwan: Lessons from TSOC-HFreF registry'. Together they form a unique fingerprint.

Cite this